RSSCategory: Government

Leica Biosystems to Advance Artificial Intelligence in Pathology as part of UK Life Sciences Sector Deal

| December 21, 2017 | 0 Comments

The United Kingdom continues adoption of digital pathology including this latest news between Leica Biosystems and the UK government in Leica’s latest announcement of leveraging artificial intelligence through the UK Office of Life Sciences.  Newcastle, UK, Dec 21, 2017 – A transformative sector deal was announced between companies of the UK life sciences sector and […]

Continue Reading

XIFIN Taps FrontRunnerHC for Integrated Insurance Detection Within RPM 9 to Help Labs Maximize Reimbursement

| December 18, 2017 | 0 Comments

Best-of-breed solution and real-time integration drives return on investment for XIFIN RPM 9 customers seeking greater revenues and workflow efficiencies; average FrontRunnerHC customers realize nearly 40% increase in coverage discovery XIFIN, Inc., the healthcare information technology company revolutionizing the business of healthcare diagnostics, recently announced the company has teamed with FrontRunnerHC and integrated its PatientRemedi insurance discovery […]

Continue Reading

ACLA Files Lawsuit Challenging CMS Implementation of PAMA

| December 18, 2017 | 0 Comments

As reported by GenomeWeb among many media outlets, in an anticipated move, the American Clinical Laboratory Association filed a lawsuit last Monday against Acting Secretary of the US Department of Health and Human Services Eric Hargan, challenging the process by which the Centers for Medicare & Medicaid Services set prices for laboratory tests under the Protecting Access to […]

Continue Reading

Health Insurers Making It Tougher for Clinical Lab and Pathology Test Claims to Get Paid: Steps to Help Labs with Patient Billing, Out-of-Network Claims, Brutal Audits, and Use of Contract Sales Reps

| November 28, 2017 | 0 Comments

Pathology Webinars, LLC FOR IMMEDIATE RELEASE Media Contact: Chris Garcia chris@pathologywebinars.com   AUSTIN, Texas (November 28, 2017) Getting paid for lab test claims is becoming the #1 issue for the nation’s clinical laboratories and pathology groups. Private health insurers and Medicare contractors are enacting harsh requirements, causing a growing proportion of lab test claims to […]

Continue Reading

Dark Daily Webinar: Tougher Lab Regulations and New Legal Issues in 2018: More Frequent Payer Audits, Problems with Contract Sales Reps, Increased Liability for CLIA Lab Directors, Proficiency Testing Violations, and More

| November 6, 2017 | 0 Comments

Join the webinar, Wednesday Nov. 8th – Register Now Attention clinical laboratory and pathology group execs: learn the steps you and your management team need to take NOW to mitigate risk and keep your lab organization financially strong! Looking forward into 2018, Medicare Part B clinical laboratory price cuts are not the only big story. […]

Continue Reading

XIFIN Highlights Flaws in CMS 2018 Draft PAMA Pricing

| September 25, 2017 | 0 Comments

Rate Setting Not Market-based and Circumvents Legislative Intent SAN DIEGO, Calif., Sept. 25, 2017 /PRNewswire/ — XIFIN, Inc., the healthcare information technology company revolutionizing the business of healthcare diagnostics, has conducted an initial review of the draft laboratory rates published on Sept. 22 by the Centers for Medicare and Medicaid Services for 2018 clinical laboratory tests under the Protecting Access […]

Continue Reading

WSI Device Clearances After the Philips De Novo Classification: An Outlook on the Regulatory Road Ahead

| September 22, 2017 | 0 Comments

By Christopher Ivicevich, Director of Regulatory Affairs & Quality Compliance, OptraSCAN With the recent shift in the industry as the result of this decision, a common question is “What lies in store for digital pathology system manufacturers in the wake of the FDA granting Philips’ de novo classification request for its IntelliSite device?” First, What […]

Continue Reading

Promega Intends to Seek FDA Approval for Microsatellite Instability Assay to Assist in Strategic Cancer Decisions

| July 9, 2017 | 0 Comments

Promega Corporation intends to seek FDA approval and CE-IVD marking for a commercially available Microsatellite Instability (MSI) assay to assist oncologists and pathologists in determining colorectal cancer decisions. The current Promega Research Use Only MSI Assay has been available and used in the market as part of Lab-Developed Tests since 2004 and is considered the […]

Continue Reading

Q&A with Philips Digital Pathology

| June 23, 2017 | 0 Comments

I recently had an opportunity to speak with Esther Abels, Director of Regulatory, Clinical and Medical Affairs for Philips Digital Pathology Solutions about Philips’ recent approval to market their Philips Intellisite Pathology System (PIPS) for primary diagnosis of biopsies and excisions in the United States. My thanks to Esther and Philips’ marketing team for their […]

Continue Reading

Tomorrow’s Webinar from Philips: Unlocking the Full Potential of Digital Pathology

| June 12, 2017 | 0 Comments

Tuesday, June 13th, Philips Digital Pathology Solutions will host two webinars for: North America: 10:00 AM – 11:00 AM EDT Register Asia & Europe: 3:00 PM – 4:00 PM SGT Register Philips IntelliSite Pathology Solution is now available for primary diagnostic use in the USA; but what does this news mean for the field of pathology? In […]

Continue Reading

FDA Approval of Immunotherapy For MSI-High or Mismatch Repair Deficient Tumors

| June 5, 2017 | 0 Comments

Last month the FDA approved pembrolizumab (KEYTRUDA) for adult and pediatric patients with with metastatic or unresectable, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment. KEYTRUDA has also been approved fro MSI-H or dMMR colorectal cancers that have progressed following treatment with conventional chemotherapies. The immunooncology/immunotherapy story is fascinating. […]

Continue Reading

What is Wrong with the Veterans Administrations Hospitals?

| May 29, 2017 | 0 Comments

This past Memorial Day weekend I gave a lot of thought to those who have passed defending our freedoms and way of life as well as those who have served and survived to be cared for by our society. About 3 years ago stories began to break about a scandal involving a Veterans Administration (VA) […]

Continue Reading

What does FDA Approval Mean for the Digital Pathology Market? Part 1

| May 15, 2017 | 0 Comments

Much is being said, written and discussed about the recent FDA clearance for Philips digital pathology solution for primary surgical pathology diagnosis. Of course, this means an advantage for Philips right now in the market as the only FDA approved whole slide imaging system for primary diagnosis. For groups and hospitals that appreciate the two main […]

Continue Reading

Webinar: Philips IntelliSite Pathology Solution Now Available for Primary Diagnostic Use in the U.S.

| April 30, 2017 | 0 Comments

Thu, May 4th, 2017 11:00 AM EST (1 hour) As a leader in the field, Philips is a driver of the adoption of digital pathology. Our solution was developed with the aim to increase efficiency and collaboration in your clinical lab. We are very proud to announce the Philips Intellisite Pathology Solution is the first, […]

Continue Reading